The US Afinitor drug market is supported by the broad therapeutic role of everolimus across oncology and tuberous sclerosis complex (TSC)-related conditions. AFINITOR is approved for multiple indications, including certain advanced breast cancers, neuroendocrine tumors, renal cell carcinoma, and TSC-associated tumors, while AFINITOR DISPERZ extends its use to SEGA and TSC-associated...